Albus Health has appointed Jonathan Day as Head of Quality Assurance and Regulatory Affairs and Dr Samantha Macro as fractional Chief Financial Officer. The company develops contactless nocturnal health monitoring systems for clinical trials. Day brings over 25 years of experience in medical devices and Software as a Medical Device across the US, UK, and Switzerland. Macro has more than 20 years of finance leadership experience in biotech and pharma, including roles at AstraZeneca, MedImmune, and Cambridge Antibody Technology. Albus Health's flagship Albus Home system uses sensors and AI to capture nocturnal data including cough, vital signs, and sleep parameters. The platform operates in more than 50 countries, supporting pharmaceutical companies, academic institutions, and patient advocacy groups.